US20200039938A1 - Kdm4 inhibitors - Google Patents

Kdm4 inhibitors Download PDF

Info

Publication number
US20200039938A1
US20200039938A1 US16/498,714 US201816498714A US2020039938A1 US 20200039938 A1 US20200039938 A1 US 20200039938A1 US 201816498714 A US201816498714 A US 201816498714A US 2020039938 A1 US2020039938 A1 US 2020039938A1
Authority
US
United States
Prior art keywords
methyl
amino
compound
kdm4
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/498,714
Other languages
English (en)
Inventor
Roland Schüle
Eric Metzger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Albert Ludwigs Universitaet Freiburg
Celgene Quanticel Research Inc
Original Assignee
Albert Ludwigs Universitaet Freiburg
Celgene Quanticel Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Ludwigs Universitaet Freiburg, Celgene Quanticel Research Inc filed Critical Albert Ludwigs Universitaet Freiburg
Priority to US16/498,714 priority Critical patent/US20200039938A1/en
Publication of US20200039938A1 publication Critical patent/US20200039938A1/en
Assigned to ALBERT-LUDWIGS-UNIVERSITY FREIBURG, CELGENE QUANTICEL RESEARCH, INC. reassignment ALBERT-LUDWIGS-UNIVERSITY FREIBURG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SCHÜLE, Roland, METZGER, ERIC
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Definitions

  • the embodiments described herein relate to compounds and methods for inhibiting the activity of the enzyme lysine demethylase 4 (KDM4).
  • KDM4 lysine demethylase 4
  • the present embodiments provide compounds and methods for inhibiting the enzymatic activity of KDM4 and treating cancers. More specifically, an aspect of the present embodiments provides substituted pyridine derivatives that inhibit KDM4 (“KDM4(i)”) and exhibit unique preclinical characteristics. At least one embodiment provides a potent pan-KDM4(i), Compound I, that specifically blocks the demethylase activity of KDM4A, 4B, 4C, and 4D, but not that of other KDM family members. KDM4(i) anti-tumor properties were validated under conditions recapitulating patient tumors.
  • Another aspect of the present embodiments provides a method to screen KDM4(i) in triple-negative breast cancer stem-cells (BCSCs) prepared from individual patient tumors after neoadjuvant chemotherapy and propagated in vitro. Limiting dilution orthotopic xenografts of these BCSCs faithfully regenerated original patient tumor histology and gene expression.
  • KDM4(i) as described herein blocks proliferation, sphere formation, and xenograft tumor growth of BCSCs prepared according to the method.
  • KDM4(i) compounds abrogate expression of EGFR, a driver of therapy-resistant, triple-negative breast tumor cells via inhibition of the KDM4A demethylase activity. This activity is particularly relevant in the context of BCSC from triple-negative tumors.
  • the present embodiments provide a unique BCSC culture system as a basis for therapeutic compound identification, and demonstrate that KDM4 inhibition is a therapeutic strategy for the treatment of cancers including triple-negative breast cancer.
  • FIG. 1A to FIG. 1H present data related to characterization of breast cancer stem cells (BCSC), and cell lines and xenografts derived therefrom.
  • FIG. 1A shows representative growth data for a limiting-dilution assay of BCSC1 cell xenografts in immunocompromised mice.
  • FIG. 1B shows immunohistochemical analysis of the original BCSC1 patient tumor and the BCSC1 xenograft tumor comprising hematoxylin and eosin (H&E), anti-CK8, anti-Ki67, anti-E-cadherin, and anti-vimentin staining. Scale bar: 100 am.
  • FIG. 1A shows representative growth data for a limiting-dilution assay of BCSC1 cell xenografts in immunocompromised mice.
  • FIG. 1B shows immunohistochemical analysis of the original BCSC1 patient tumor and the BCSC1 xenograft tumor comprising hematoxylin and eosin (
  • FIG. 1C shows anti-ER, anti-PR and HER2 immunohistochemical staining of the original BCSC1 patient tumor, the BCSC1 xenograft tumor, and positive control sample.
  • ER estrogen receptor
  • PR progesterone receptor
  • HER2 human epidermal growth factor 2
  • scale bar 100 am.
  • FIG. 1D provides an unsupervised hierarchical cluster analysis of RNA microarray data presented as a cluster dendrogram. Samples are original patient tumors BCSC1, BCSC2, BCSC3, and BCSC4; derived BCSC1-4 lines; and BCSC1-4 xenograft tumors derived from the BCSC lines 1-4.
  • FIG. 1E is representative pictures showing the cellular phenotype of BCSC1 cells cultured in 3D (top panel) and 2D (bottom panel) conditions. Scale bar, 100 am.
  • FIG. 2A to FIG. 2F demonstrate that KDM4 inhibitors (“KDM4(i)”) are potent inhibitors of BCSC1 cells.
  • FIG. 2A shows anti-KDM4A, antiKDM4B, anti-KDM4C, anti-KDM4D, and anti-tubulin western blots. Samples are lysates from HEK293T; HEK293T transfected with expression plasmids expressing KDM4A, KDM4B, KDM4C, or KDM4D; BCSC1; and BCSC2 cells.
  • FIG. 2B illustrates the formula/structure of a particular embodiment of KDM4(i), Compound I.
  • FIG. 3A to FIG. 3J shows that a KDM4(i) can target BCSC through EGFR regulation.
  • FIG. 3A is a pie chart displaying the number of genes that are differentially regulated in BCSC1 cells upon treatment with a KDM4(i): the transcriptome of BCSC1 cells with or without KDM(i) exposure (580 genes, p ⁇ 1e-5): 254 upregulated genes and 326 downregulated genes.
  • FIG. 3B is a pie chart showing genomic distribution of KDM4A in BCSC1 cells as determined by ChIP-seq analysis: KDM4A peaks (172,692 peaks): 12.5% promoter; 40.5% intergenic; 41.0% intron; 3.3% exon; and 2.7% 3′UTR.
  • FIG. 3A is a pie chart displaying the number of genes that are differentially regulated in BCSC1 cells upon treatment with a KDM4(i): the transcriptome of BCSC1 cells with or without KDM(i) exposure (580 genes, p ⁇
  • FIG. 3C is a Venn diagram showing the intersection and number of genes where KDM4A is present on the promoter region with genes that are differentially regulated in BCSC1 cells upon treatment with a KDM4(i). A hypergeometric test calculated significance of overlaps (c; p ⁇ 10-50).
  • FIG. 3D illustrates KEGG pathways analyses (pathway enrichment analysis/common pathways) (pathways enriched for the set of 419 genes depicted in FIG. 3C ).
  • FIG. 3E reflects mRNA level analysis, more specifically a heat-map representing the mRNA levels found in BCSC1 cells cultured in absence ( ⁇ ) and presence (+) of a KDM4(i).
  • the 37 direct target genes of KDM4A represent a gene signature common for all the pathways represented in FIG.
  • FIG. 3G and FIG. 3H are photos of anti-EGFR, anti-KDM4A, and anti-tubulin western blots generated from lysates of BCSC1 cells in the absence ( ⁇ ) and presence (+) of a KDM4(i) ( FIG. 3G ); or BCSC1 cells treated with shRNA control (Ctrl) or anti-KDM4A shRNA ( FIG. 3H ).
  • FIG. 3G and FIG. 3H are photos of anti-EGFR, anti-KDM4A, and anti-tubulin western blots generated from lysates of BCSC1 cells in the absence ( ⁇ ) and presence (+) of a KDM4(i) ( FIG.
  • FIG. 3I is a graph showing meta-analysis of sequencing read density based on H3K9me3 ChIPseqs around KDM4A peaks in BCSC1 cells cultured in the presence (gray) or absence (black) of a KDM4(i). A hypergeometric test was done to calculate the significance of the overlaps; p ⁇ 10-50).
  • FIG. 3J shows BCSC1 cells ChIP-Seq tracks analysis in the absence (dark) or presence (light) of a KDM4(i). Normalized levels of H3K9me3 tracks at the EGFR promoter.
  • FIG. 4A to FIG. 4F show that KDM4(i) inhibits xenograft tumor growth from BCSC1 cells. Mice bearing BCSC1 xenograft tumors were treated for 21 consecutive days with either vehicle or a KDM4(i).
  • FIG. 4A is a photo of representative xenograft BCSC1 tumors isolated from individual animals after 21 day of treatment.
  • FIG. 4A is a photo of representative xenograft BCSC1 tumors isolated from individual animals after 21 day of treatment.
  • FIG. 5A to FIG. 5G demonstrates that BCSC2 cells and xenograft recapitulate the original tumor patient.
  • FIG. 5A graphs representative growth curves for a limiting-dilution/BCSC2 xenograft formation assay of BCSC2 cells using BCSC2 xenografts in an immunocompromised mouse model.
  • FIG. 5B shows photos of hematoxylin and eosin (H&E), anti-CK8, anti-Ki67, anti-E-cadherin, and anti-vimentin immunohistochemical staining. Samples are the original BCSC2 patient tumor and the BCSC2 xenograft tumor.
  • FIG. 5A graphs representative growth curves for a limiting-dilution/BCSC2 xenograft formation assay of BCSC2 cells using BCSC2 xenografts in an immunocompromised mouse model.
  • FIG. 5B shows photos of hematoxylin and eosin (H
  • FIG. 5C shows photos of anti-ER, anti-PR and HER2 immunohistochemical staining of the original BCSC2 patient tumor and the BCSC2 xenograft tumor.
  • ER estrogen receptor
  • PR progesterone receptor
  • HER2 human epidermal growth factor 2
  • scale bar 100 am.
  • FIG. 5D shows representative photos of BCSC2 cells cultured in 3D and 2D conditions.
  • FIG. 6A to FIG. 6F show that a KDM4(i) is a potent inhibitor of BCSC2 cells.
  • FIG. 6A is a graph reflecting a cell proliferation assay in which BCSC2 cells were culture in the absence ( ⁇ ) or presence of 10 nm ( ⁇ ) or 50 nm ( ⁇ ) KDM4(i).
  • FIG. 6A is a graph reflecting a cell proliferation assay in which BCSC2 cells were culture in the absence ( ⁇ ) or presence of 10 nm ( ⁇ ) or 50 nm ( ⁇ ) KDM4(i).
  • FIG. 6D is a bar graph of primary and secondary sphere-forming capacity of BCSC2 cells in Matrigel. For the primary week, cells were culture in absence ( ⁇ ) and presence (50 nM) of a KDM4(i). Comparisons via one-way ANOVA. Data represent means ⁇ s.e.m.*P ⁇ 0.05, **P ⁇ 0.01, ***P ⁇ 0.001.
  • FIG. 7A to FIG. 7K demonstrate that an embodiment of a KDM4(i) targets BCSC2 through EGFR regulation.
  • FIG. 7A is a Venn diagram of BCSC1 cells and KDM4A locations, displaying the number of locations in control BCSC1 cells (Ctrl (172,639)) and BCSC1 cells infected with an adenovirus expressing an shRNA against KDM4A (KDM4A KD (3,215)) showing an overlap of 1110 locations.
  • FIG. 7B and FIG. 7C show data of proliferation assays of BCSC cells, more specifically representative proliferation of BCSC1 ( FIG. 7B ) and BCSC2 ( FIG.
  • FIG. 7F and FIG. 7G show BCSC1 ( FIG. 7F ) and BCSC2 ( FIG. 7G ) 3D sphere-forming capacity in anchorage-independent growth assay in the absence (left bar) and the presence of 1 ⁇ M (middle bar) or 10 ⁇ M (right bar) Erlotinib.
  • FIG. 7H and FIG. 7I show anti-EGFR, anti KDM4A, and anti-tubulin western blots. Samples are lysates from BCSC2 cells cultured in the absence and presence of a KDM4(i) ( FIG. 7H ); or treated with an shRNA control (Ctrl) or shRNA against KDM4A ( FIG. 7I ). FIG.
  • 7J are two pie charts displaying genomic distribution of H3K9me3 in BCSC1 cells in the absence (H3K9me3 peaks: 141,722 peaks) or presence of KDM4(i) (H3K9me3 peaks: 144,266 peaks) as determined by ChIP-seq analysis: Vehicle: 6.2% promoter; 47.3% intergenic; 41.2% intron; 2.8% exon; 2.4% 3′UTR; +KDM4(i): 6.2% promoter; 47.7% intergenic; 40.7% intron; 2.9% exon; 2.4% 3′UTR.
  • 7K is a Venn diagram showing number and intersection of KDM4A and H3K9me3 locations in BCSC1 cells cultured in the absence or presence of a KDM4(i). A hypergeometric test was done to calculate the significance of the overlaps (i; p ⁇ 10 ⁇ 50 ).
  • FIG. 8A to FIG. 8G demonstrate that a KDM4(i) inhibits xenograft tumor growth in mice bearing BCSC2 xenograft tumors treated for 21 consecutive days with either vehicle or a KDM4(i).
  • FIG. 8A is photos of representative xenograft BCSC2 tumors isolated from individual animals after 21 day of treatment.
  • FIG. 8A is photos of representative xenograft BCSC2 tumors isolated from individual animals after 21 day of treatment.
  • FIG. 8D shows representative images of tumors
  • FIG. 8F and FIG. 8G show body weight of mice bearing BCSC1 xenograft tumors ( FIG. 8F ) or BCSC2 xenograft tumors ( FIG. 8G ) over the treatment time-span of 21 consecutive days with either vehicle or a KDM4(i). Data represent means ⁇ s.e.m.
  • FIG. 9 presents a series of illustrations related to KGM4 structure and function.
  • A is a schematic structure of four KDM4 proteins. The JmjN domain is required for the activity of the JmjC catalytic center.
  • B shows modes of KDM4 function as demethylases or independent of enzymatic activity.
  • C shows SDH, FH and IDH in the Krebs cycle. Succinate accumulates upon SDH or FH mutation, while neomorphic IDH mutations lead to 2-hydroxyglutarate production. This figure is reproduced from Berry & Janknecht, KDM 4 /JMJD 2 Histone Demethylases: Epigenetic Regulators in Cancer Cells, 73(10) Cancer Res. 2936 (2013).
  • the embodiments described herein provide therapy particularly indicated when the disease state of the subject (e.g., cancer or neoplastic disease) is associated with epigenetics or the epigenetic state of the subject.
  • the disease state of the subject e.g., cancer or neoplastic disease
  • epigenetics is the study of heritable changes in gene expression caused by mechanisms other than the underlying DNA sequence.
  • Molecular mechanisms that play a role in epigenetic regulation include DNA methylation and chromatin/histone modifications.
  • the genomes of eukaryotic organisms are highly organized within the nucleus of the cell. Tremendous compaction is required to package the 3 billion nucleotides of the human genome into the nucleus of a cell.
  • Chromatin is the complex of DNA and protein that makes up chromosomes. Histones are the major protein component of chromatin, acting as spools around which DNA winds.
  • chromatin There are six classes of histones (HI, H2A, H2B, H3, H4, and H5) organized into two groups: core histones (H2A, H2B, H3, and H4) and linker histones (HI and H5).
  • the basic unit of chromatin is the nucleosome, which consists of about 147 base pairs of DNA wrapped around the core histone octamer, consisting of two copies each of the core histones H2A, H2B, H3, and H4. Changes in chromatin structure are affected by covalent modifications of histone proteins and by non-histone binding proteins.
  • DNA methylation, acetylation, and other post-translational modifications of the nucleosome histone proteins alter chromatin organization and gene expression without altering the underlying DNA sequence.
  • alterations in the cellular epigenetic environment, and not only primary genetic mutations play an important role in tumor formation, progression and resistance to treatment, because epigenetic modification may influence if, when, or where specific genes are expressed.
  • Epigenetic modification is a dynamic and reversible process that is written, erased, and read by various enzyme families. Several classes of enzymes are known which modify histones at various sites. Arrowsmith et al., 11 Nature Rev. Drug Discov. 384 (2012). See also, U.S. Pat. No. 9,255,097.
  • Histone “demethylases” are enzymes that remove at least one methyl group from a polypeptide, and particular demethylases may demethylate either a mono-, di- or a tri-methylated substrate. Histone demethylases can act on a substrate including methylated core histones, mononucleosomes, dinucleosomes, oligonucleosomes, peptides, or chromatin (e.g., in a cell-based assay).
  • Example lysine-specific demethylases include lysine-specific demethylase 1 (LSD1 or KDM1), that demethylates both mono- and di-methylated H3K4 or H3K9 using flavin as a cofactor; and a family of demethylases characterized by a ⁇ 150 amino acid-long Jumonji C (JmjC) domain (e.g., jumonji domain-containing histone demethylase 1 [JHDM1/KDM2A]). See, e.g., U.S. Pat. No. 9,255,097; WO 2015/200709.
  • JmjC Jumonji domain-containing histone demethylase 1
  • human LSD1 and its paralog, LSD2 demethylate both mono- and di-methylated histone H3 lysine 4 (H3K4) and H3K9 via a FAD-dependent amine oxidation reaction.
  • the Jumonji C domain-containing (JMJD) proteins act through a dioxygenase reaction mechanism that requires Fe 2+ , O 2 , and 2-oxoglutarate to demethylate histones.
  • the JMJD catalytic step is the hydroxylation of a lysine methyl group, which converts it to a hydroxymethyl moiety that spontaneously leaves the nitrogen center of the lysine and releases formaldehyde.
  • JMJD proteins in principle, to demethylate tri-, di- and mono-methylated lysine residues, whereas LSD1/2 cannot attack trimethylated lysine residues due to the requirement of a free electron pair on the methylated nitrogen.
  • Most of the JMJD proteins demethylate H3K4, H3K9, H3K27, H3K36, or H4K20, but the enzymatic activity of several JMJD proteins remains unknown, some JMJD demethylases may have methyl-arginine demethylase activity, and some other JMJD proteins may have no catalytic activity at all.
  • JMJD proteins include some thirty human members phylogenetically clustered into seven subfamilies: JMJD2, JHDM1, JHDM2, JHDM3, JARID, PHF2/PHF8, UTX/UTY, and JmjC domain only. See, e.g., U.S. Pat. No. 9,447,046.
  • KDM4 K (lysine) demethylase 4.
  • the KDM4 subfamily includes KDM4A, B, C, and D.
  • KDM4 can recognize di- and tri-methylated H3K9 and H3K36, as well as trimethylated H1.4K26, as substrates.
  • ectopic expression of KDM4 family members dramatically decreased levels of tri- and di-methylated H3K9, and increased levels of mono-methylated H3K9, which then delocalized heterochromatin protein 1 and reduced overall levels of heterochromatin in vivo.
  • KDM4 demethylases catalyze the demethylation of both the repressive H3K9me3 mark and the H3K36me3 mark, the latter linked to transcriptional elongation.
  • Frank et al. Therapeutic promise of cancer stem cell concept, 120 J. Clin. Invest. 41 (2010).
  • the present embodiments provide use of substituted pyridine derivative compounds for inhibiting the enzymatic activity of KDM4, and advantageously treating cancer.
  • an embodiment of KDM4(i) described herein as Compound I exhibited striking selectivity and efficacy in inhibiting breast cancer tumors, importantly, tumors of triple-negative breast cancer.
  • the present embodiments provide a KDM4 inhibitor with unique preclinical characteristics.
  • This KDM4(i) is a highly potent pan-KDM4 inhibitor that specifically blocks the demethylase activity of KDM4A, B, C, and D but not that of the other members of the KDM family.
  • the KDM4(i) anti-tumor properties were validated under conditions recapitulating patient tumors.
  • Another aspect of the present embodiments provides a method to isolate and grow triple-negative breast cancer stem-cells (BCSCs) from individual patient tumors after neoadjuvant chemotherapy.
  • BCSCs triple-negative breast cancer stem-cells
  • Limiting dilution orthotopic xenografts of these BCSCs faithfully regenerated original patient tumor histology and gene expression.
  • KDM4(i) blocks proliferation, sphere formation and xenograft tumor growth of BCSCs.
  • KDM4(i) abrogates expression of EGFR, a driver of therapy-resistant, triple-negative breast tumor cells via inhibition of the KDM4A demethylase activity.
  • the present embodiments provide a unique BCSC culture system as a basis for therapeutic compound identification and demonstrate that KDM4 inhibition is a new therapeutic strategy for the treatment of triple-negative breast cancer.
  • KDM4 demethylases Dysregulation of the KDM4 demethylases has been documented in a variety of cancers including breast cancer. Berry & Janknecht, 2013. It has been shown that KDM4 controls tumor cell proliferation, particularly in aggressive breast cancers. Ye et al., Genetic alterations of KDM 4 subfamily & therapeutic effect of novel demethylase inhibitor in breast cancer, 5 Am. J. Cancer. Res. 1519 (2015). Therapy resistance and metastatic dissemination are the main problems faced during breast cancer treatment. Breast cancer stem-cells have been suggested to be responsible for both therapy resistance and metastatic dissemination. Chu et al., 2014; Ansieau, EMT in breast cancer stem cell generation, 338 Cancer Lett. 63 (2013).
  • KDM4 demethylases may provide effective therapeutic targets for the treatment of cancer.
  • a screen was developed to identify novel KDM4 inhibitors.
  • a new 3D cultivation method was developed as described herein, using defined serum-free conditions and a low oxygen environment to enrich BCSCs from individual patient tumors after neoadjuvant chemotherapy.
  • BCSC1 BCSC1, 2, 3, and 4
  • All lines originated from primary breast tumors that were Triple-negative: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) negative; all xenograft tumors established from these lines were triple-negative.
  • ER estrogen receptor
  • PR progesterone receptor
  • HER2 human epidermal growth factor receptor 2
  • BCSC1-4 patient original tumor, BCSC1-4 cell lines, and BCSC1-4 xenografts Patient Tumor Neoadjuvantly administered Xenograft Tumor Primary chemotherapeutic Tumor ID Diagnosis drugs Classification formation BCSC1 IC FEC, FAC, TAC, TC, Triple-negative 36/38 Cisplatin BCSC2 IDC Taxol, Myocet Triple-negative 30/43 BCSC3 IDC EC, Taxotere Triple-negative 7/7 BCSC4 MC AC, Taxol, GemCa Triple-negative 2/2 BCSC1-4: breast cancer stem-cells 1-4; IC: invasive carcinoma; IDC: invasive ductal carcinoma; MC: metaplastic carcinoma; FEC: 5FU/epi-rubicin/cyclophosphamide; FAC: 5FU/doxorubicin/cyclophosphamide; TAC: docetaxel/doxo-rubicin/cyclophosphamide; TC: docetaxel/cyclo
  • the estimated frequency of cancer stem-cells in the BCSC cultures was determined (by limiting dilution cell number transplantation) to range from 0.26 to 179 in 1 ⁇ 10 5 cells, as reflected in Table 2:
  • FIG. 1D The BCSC lines clustered separately from host tumor and xenograft, specifying the unique properties of these cells. Nevertheless, they clustered within the host tumor subtype depicting a close correlation between the three entities.
  • FIG. 1D The BCSC lines clustered separately from host tumor and xenograft, specifying the unique properties of these cells. Nevertheless, they clustered within the host tumor subtype depicting a close correlation between the three entities.
  • the BCSCs were also cultivated in a 3D and 2D environment, growing as spheroids and mainly epithelial clusters, respectively.
  • FIG. 1E ; FIG. 5D When challenged in an anchorage-independent growth assay, BCSC1 and BCSC2 cells demonstrated a sphere-forming capacity of 11% and 17%, respectively.
  • FIG. 1F ; FIG. 5E Unsorted BCSCs, isolated and cultivated as described above, expressed to varying degrees the well-known CSC markers such as CD24/CD44 ( FIG. 1G ; FIG. 5I ) and CD49f/EpCAM ( FIG. 1H ; FIG. 5J ). Taken together, the data show that BCSCs from triple-negative breast tumors can be isolated and cultivated directly from patient tissue to provide an in vitro cellular platform representing this disease. This allows for the identification and validation of novel cancer targeting strategies in vitro and in vivo.
  • KDM4A was expressed at high levels in both BCSC1 and BCSC2 cells. These cells also exhibited heterogeneous expression levels of KDM4B, KDM4C, and KDM4D. These observations indicate that KDM4 are therapeutic targets for treatment of BCSC populations. Accordingly, a screen to characterize KDM4(i) was performed to explore compounds suitable for treating cancers, in particular cancers such as therapy resistant clonal BCSC-originating tumors.
  • KDM4(i) This screen confirmed the efficacy of a particular KDM4(i) shown in FIG. 2B (Compound I). Importantly, this KDM4(i) specifically blocked the demethylase activities of KDM4A, 4B, 4C, and 4D (IC 50 ⁇ 105 nM) but did not affect the demethylase activity of the other KDMs. Of note, KDM4(i) exhibited a weak effect on the demethylase activity of KDM5B. Table 3 shows the half-maximal inhibitory concentration (IC 50 ) of a Compound I against KDM demethylases:
  • KDM4(i) IC 50 per KDM4 member KDM4 family member Compound I IC 50 ( ⁇ M) KDM4A 0.104 KDM4B 0.056 KDM4C 0.035 KDM4D 0.104 KDM2A >10 KDM2B >10 KDM5B 0.750 KDM6A >10 KDM6B >10
  • KDM4(i) strongly inhibited proliferation of several types of cancer cell lines, including the triple-negative breast cancer cells: MDA-MB-231.
  • Table 4 shows the half-maximal effective concentration (EC 50 ) of Compound I on various cancer cell lines as shown in a 7-day cell MTS assay:
  • KDM4(i) such as Compound I has properties that demonstrate its suitability for use in the clinic.
  • Example pharmacokinetic data is shown in Table 5:
  • FIG. 7A This finding prompted the characterization of the KDM4A cistrome intersection with the KDM4(i) transcriptome.
  • KDM4A was present at the promoter of 419 genes (72%).
  • FIG. 3C Pathway analysis for these genes revealed an ‘EGF receptor signaling pathway’ among the top scoring pathways.
  • FIG. 3D Importantly, the top scoring pathways share a common gene signature of 37 direct KDM4A target genes that are differentially regulated upon treatment with KDM4(i).
  • FIG. 3E Further, qRT-PCR analysis verified that treatment with KDM4(i) genes reduced the expression levels of genes, such as VCAN, PRR5, ATF4, EGR1, FST, RUNX1, and, importantly, EGFR.
  • FIG. 3F .
  • EGFR is an emerging therapeutic target associated with poor clinical outcome of triple-negative breast cancer. Hsu & Hung, 2016. To unravel the importance of EGFR signaling in growth of BCSC cells, BCSC1 and BCSC2 cells were treated with a specific EGFR inhibitor: erlotinib. Treatment with erlotinib blocked proliferation of both BCSC1 and BCSC2 cells.
  • FIG. 7B - FIG. 7E Furthermore, the 3D-colony forming capacity of both BCSC1 and BCSC2 cells was dramatically reduced upon treatment with erlotinib.
  • FIG. 7F , FIG. 7G Together, these data demonstrated that EGFR controls growth of BCSC cells.
  • FIG. 3G shows that EGFR is a direct KDM4A target, whether knockdown of KDM4A affects EGFR protein levels was determined. As shown, adenoviral-mediated knockdown of KDM4A lead to reduced levels of EGFR in both BCSC1 and BCSC2 cells.
  • FIG. 3H ; FIG. 7I These data indicate that in BCSCs, KDM4(i) inhibition of KDM4A blocks EGFR expression.
  • KDM4A is a demethylase of the repressive H3K9me3 mark
  • KDM4(i) upon inactivation of KDM4A by KDM4(i) an increase in H3K9me3 might be observed.
  • a ChIP-seq assay using an anti-H3K9me3 antibody identified 141,722 high-confidence H3K9me3 peaks in untreated cells and 144,266 peaks in KDM4(i)-treated cells.
  • FIG. 7J Overlap of KDM4A locations with H3K9me3 locations in presence and absence of KDM4(i) revealed that 81,717 locations were co-occupied.
  • FIG. 7K A global increase of the H3K9me3 reads over the KDM4A peaks was observed.
  • FIG. 3I Similarly, on the EGFR promoter, an increase of the repressive H3K9me3 mark over the KDM4A peak was observed subsequent to inactivation by KDM4(i).
  • FIG. 3J These data correlate with the transcriptional repression that is observed upon KDM4(i) treatment.
  • FIG. 3F In summary, treating BCSCs with KDM4(i) targets EGFR, a main driver of therapy-resistant triple-negative breast tumor cells, by inhibiting KDM4A demethylase activity.
  • KDM4(i) the impact of KDM4(i) on the growth of BCSC1 and BCSC2 tumor xenografts was studied in immunocompromised NOD/SCID mice carrying budding xenograft tumors following 21 days of treatment with KDM4(i).
  • Treatment with KDM4(i) strongly affected tumor growth and final tumor weight of both BCSC1 and BCSC2 xenografts.
  • treatment with KDM4(i) never affected the total weight of the mice.
  • FIG. 8F , FIG. 8G treatment of KDM4(i) affected expression of KDM4A target genes in a similar way as observed in cell culture.
  • FIG. 3F the impact of KDM4(i) on the growth of BCSC1 and BCSC2 tumor xenografts was studied in immunocompromised NOD/SCID mice carrying budding xenograft tumors following 21 days of treatment with K
  • the present embodiments establish a novel culture method that allows for isolation and growth of BCSC lines isolated from individual patient tumors after neoadjuvant chemotherapy.
  • Limiting dilution BCSC xenografts faithfully recapitulate parental patient tumors and BCSCs, BCSC xenografts, and the parental tumors share a highly similar transcriptome profile. Therefore, these models are ideal tools for identification and validation of novel therapeutics.
  • At least one embodiment establishes a method of screening KDM4 inhibitory activity of a KDM4 inhibitory compound in primary breast cancer stem cells comprising the steps of: (1) obtaining breast tumor material; (2) mechanically dissociating the tumor material; (3) treating the tumor material with at least one DNAse, dispase, or thermolysin; (4) diluting the tumor material in buffer; (5) straining the dissociated treated tumor material to obtain tumor cells; (6) optionally removing red blood cells with lysis buffer; (7) washing the tumor cells in cell culture media; (8) culturing the washed tumor cells in a stem cell enrichment medium comprising a 1:1 ratio of (a) liquid medium and (b) solid matrix, wherein (a) comprises: mammary epithelial basal medium, serum-free supplement, amphotericin, penicillin-streptomycin, epidermal growth factor, fibroblast growth factor, heparin, gentamicin, and Rho kinase inhibitor; (9) incubating the stem cell enrichment culture at 37
  • the present embodiments not only support the pursuit of KDM4 family members as novel therapeutic targets, but provide at least one novel KDM4 inhibitor with unique preclinical characteristics that blocks proliferation of BCSCs in vitro and in vivo by targeting the EGFR pathway.
  • modulation of KDM4 activity is a promising therapeutic strategy for the treatment of cancers such as, in particular, chemotherapy-resistant breast cancer.
  • Compound I 3-([(1R)-6-[methyl(phenyl)amino]-1,2,3,4-tetrathydronaphthalen-1-yl]methyl]amino)pyridine-4-carboxylic acid, is a specific example of a substituted pyridine derivative compound comprising a disubstituted pyridine ring bearing at the 4-position a carboxylic acid, and at the 3-position a substituted amino group.
  • This and related substituted pyridine derivatives are provided in WO 2015/200709.
  • At least one embodiment provides a KDM4(i) compound having the structure of Formula I:
  • said compound includes stereoisomers and pharmaceutically acceptable salts thereof, and wherein
  • X is O or CH 2
  • R 6 is N(R 1 )(R 2 ) or O(R 2 ), in which
  • the compound is the R stereoisomer.
  • R 1 is methyl or ethyl.
  • R 2 is heteroaryl such as pyridine.
  • R 2 is substituted heteroaryl, such as pyridine substituted with alkyl such as methyl, ethyl, or cyclopropyl.
  • R 2 is aryl such as phenyl.
  • R 2 is substituted aryl, such as phenyl, substituted with halo, such as fluoro or chloro; or substituted with alkyl, such as methyl, propanyl, or cyclopropyl; or substituted with both halo and alkyl, such as fluoro and methyl; or substituted with an amino or N-containing group such as dimethylamino, azetidinyl; or substituted with a alkoxy such as ethoxy, cyclopropylmethoxy, methoxymethyl, difluoromethoxy, or trifluoromethoxy; or substituted with heterocyclyl such as oxanyl.
  • aryl such as phenyl, substituted with halo, such as fluoro or chloro
  • alkyl such as methyl, propanyl, or cyclopropyl
  • halo and alkyl such as fluoro and methyl
  • an amino or N-containing group such as dimethylamino, aze
  • R 2 is an indane moiety such as 2,3dihydro-1H-indenyl.
  • X is CH 2 and R 6 is N(R 1 )(R 2 ), in which R 1 is methyl, and R 2 is phenyl or pyridinyl.
  • KDM4(i) is 3-([[(1R)-6-[methyl(phenyl) amino]-1,2,3,4-tetrahydronaphthalen-1-yl]methyl]amino)pyridine-4-carboxylic acid.
  • the KDM4(i) is 3-([[(1R)-6-[methyl(pyridin-2-yl)amino]-1,2,3,4-tetrahydro-naphthalen-1-yl]methyl]amino)pyridine-4-carboxylic acid.
  • X is CH 2 and R 6 is N(R 1 )(R 2 ), in which R 1 is methyl, and R 2 is phenyl substituted with methyl.
  • the KDM4(i) is 3-([[(1R)-6-[methyl(4-methylphenyl)amino]-1,2,3,4-tetrahydronaphthalen-1-yl]methyl]amino)pyridine-4-carboxylic acid.
  • X is CH 2 and R 6 is N(R 1 )(R 2 ), in which R 1 is methyl, and R 2 is phenyl substituted with dimethylamino.
  • the KDM4(i) is 3-([[(1R)-6-[[4-(dimethylamino)phenyl](methyl)amino]-1,2,3,4-tetrahydronaphthalen-1-yl]methyl]amino)pyridine-4-carboxylic acid.
  • X is CH 2 and R 6 is N(R 1 )(R 2 ), in which R 1 is methyl, and R 2 is phenyl substituted with methoxymethyl, ethoxy, or difluoromethoxy.
  • KDM4(i) is 3-([[(1R)-6-[[4-(methoxymethyl)phenyl](methyl)amino]-1,2,3,4-tetrahydro-naphthalen-1-yl]methyl]amino) pyridine-4-carboxylic acid.
  • KDM4(i) is 3-([[(1R)-6-[[4-(difluoromethoxy)phenyl](methyl)amino]-1,2,3,4-tetrahydronaphthalen-1-yl]-methyl]amino) pyridine-4-carboxylic acid. In a specific embodiment, the KDM4(i) is 3 ([[(1R)-6-[(4-ethoxyphenyl)(methyl)amino]-1,2,3,4-tetrahydronaphthalen-1-yl]methyl]amino) pyridine-4-carboxylic acid.
  • X is CH 2 and R 6 is N(R 1 )(R 2 ), in which R 1 is methyl, and R 2 is pyridinyl substituted with methyl.
  • KDM4(i) is 3-([[(1R)-6-[methyl-[5-methylpyridin-2-yl) amino]-1,2,3,4-tetrahydronaphthalen-1-yl]methyl]amino)pyridine-4-carboxylic acid.
  • KDM4(i) is 3-([[(1R)-6-[methyl[6-methylpyridin-2-yl)amino]-1,2,3,4-tetrahydronaphthalen-1-yl]methyl]amino)pyridine-4-carboxylic acid.
  • X is O and R 6 is N(R 1 )(R 2 ), in which R 1 is ethyl, and R 2 is phenyl.
  • KDM4(i) is 3-([[(4R)-7-[ethyl(phenyl)amino]-3,4-dihydro-2H-1-benzopyran-4-yl]methyl]amino)pyridine-4-carboxylic acid.
  • X is O and R 6 is N(R 1 )(R 2 ), in which R 1 is methyl, and R 2 is substituted phenyl.
  • R 1 is methyl
  • R 2 is substituted phenyl.
  • the phenyl is substituted with chloro or fluoro.
  • KDM4(i) is 3-([[(4R)-7-[3-fluorophenyl)(methyl)amino]-3,4-dihydro-2H-1-benzopyran-4-yl]methyl]amino)pyridine-4-carboxylic acid.
  • KDM4(i) is 3-([[(4R)-7-[4-fluorophenyl)(methyl)amino]-3,4-dihydro-2H-1-benzopyran-4-yl]-methyl]amino)pyridine-4-carboxylic acid.
  • the KDM4(i) is 3-([[(4R)-7-[4-chlorophenyl)(methyl)amino]-3,4-dihydro-2H-1-benzopyran-4-yl]methyl]amino) pyridine-4-carboxylic acid.
  • X is O and R 6 is N(R 1 )(R 2 ), in which R 1 is methyl, and R 2 is substituted phenyl.
  • R 1 is methyl
  • R 2 is substituted phenyl.
  • the phenyl is substituted with methyl, ethyl, propyl, or cyclopropyl.
  • the KDM4(i) is 3-([[(4R)-7-[methyl(4-methylphenyl) amino]-3,4-dihydro-2H-1-benzopyran-4-yl]methyl]amino)pyridine-4-carboxylic acid.
  • the KDM4(i) is 3-([[(4R)-7-[methyl(4-ethylphenyl)amino]-3,4-dihydro-2H-1-benzopyran-4-yl]methyl]amino)pyridine-4-carboxylic acid. In a specific embodiment, the KDM4(i) is 3-([[(4R)-7-[methyl[4-propan-2-yl)phenyl]amino]-3,4-dihydro-2H-1-benzopyran-4-yl]methyl]amino)pyridine-4-carboxylic acid.
  • X is O and R 6 is N(R 1 )(R 2 ), in which R 1 is methyl, and R 2 is pyridinyl substituted with methyl, ethyl, or cyclopropyl.
  • KDM4(i) is 3-([[(4R)-7-[methyl(5-methylpyridin-2-yl)amino]-2,3-dihydro-2H-1-benzopyran-4-yl]methyl]amino)pyridine-4-carboxylic acid.
  • the KDM4(i) is 3-([[(4R)-7-[methyl (5-methylpyridin-2-yl)amino]-3,4-dihydro-2H-1-benzopyran-4-yl]methyl]amino)pyridine-4-carboxylic acid. In a specific embodiment, the KDM4(i) is 3-([[(4R)-7-[(5-cyclopropylpyridin-2-yl) (methyl)amino]-3,4-dihydro-2H-1-benzopyran-4-yl]methyl]amino) pyridine-4-carboxylic acid.
  • the KDM4(i) is 3-([[(4R)-7-[(4-cyclopropylphenyl)(methyl)amino]-3,4-dihydro-2H-1-benzopyran-4-yl]methyl]amino)pyridine-4-carboxylic acid.
  • X is O and R 6 is N(R 1 )(R 2 ), in which R 1 is methyl, and R 2 is substituted phenyl.
  • R 1 is methyl
  • R 2 is substituted phenyl.
  • the phenyl is substituted with trifluoroethyl.
  • the KDM4(i) is 3-( ⁇ [(1R)-6- ⁇ [4-(1H-imidazol-1-yl)phenyl] (methyl)amino ⁇ -1,2,3,4-tetrahydronaphthalen-1-yl]methyl ⁇ amino)pyridine-4-carboxylic acid.
  • X is O and R 6 is N(R 1 )(R 2 ), in which R 1 is methyl, and R 2 is substituted phenyl.
  • R 1 is methyl
  • R 2 is substituted phenyl.
  • phenyl is substituted with trifluoromethoxy, difluoroethoxy, or cyclopropylmethoxy.
  • KDM4(i) is 3-([[(1R)-6-[[4-(tri-fluoromethoxy) phenyl](methyl)amino 3,4-dihydro-2H-1-benzopyran-4-yl]methyl]amino)pyridine-4-carboxylic acid.
  • KDM4(i) is 3-([[(4R)-7-[[4-(difluoromethoxy)phenyl](methyl)-amino]-3,4-dihydro-2H-1-benzopyran-4-yl]methyl]amino)pyridine-4-carboxylic acid.
  • KDM4(i) is 3-( ⁇ [(1R)-6- ⁇ [4-(cyclo-propylmethoxy)phenyl](methyl)amino ⁇ -1,2,3,4-tetrahydronaphthalen-1-yl]methyl ⁇ amino)pyridine-4-carboxylic acid.
  • X is O and R 6 is N(R 1 )(R 2 ), in which R 1 is methyl, and R 2 is substituted phenyl, such as azetidinyl substituted phenyl.
  • the KDM4(i) is 3-([[(4R)-7-[[4-azetidin-1-yl)phenyl](methyl)amino]-3,4-dihydro-2H-1-benzopyran-4-yl]methyl]amino)pyridine-4-carboxylic acid.
  • X is O and R 6 is N(R 1 )(R 2 ), in which R 1 is methyl, and R 2 is substituted phenyl.
  • R 1 is methyl
  • R 2 is substituted phenyl.
  • the phenyl is substituted with oxanyl.
  • the KDM4(i) is 3-( ⁇ [(4R)-7- ⁇ methyl[4-(oxan-4-yl)phenyl]amino ⁇ -3,4-dihydro-2H-1-benzopyran-4-yl]methyl ⁇ amino)pyridine-4-carboxylic acid.
  • X is O and R 6 is N(R 1 )(R 2 ), in which R 1 is methyl, and R 2 is 2,3-dihydro-1H-indenyl.
  • the KDM4(i) is 3-([[(4R)-7-[2,3-dihydro-1H-inden-5-yl)(methyl)amino]-3,4-dihydro-2H-1-benzopyran-4-yl]methyl]amino)pyridine-4-carboxylic acid.
  • X is CH 2 and R 6 is O(R 2 ), in which R 2 is phenyl substituted with fluoro and methyl.
  • the KDM4(i) is 3-([[(1R)-6-[2-fluoro-4-methyl-phenoxy)-1,2,3,4-tetrahydronaphthalen-1-yl]methyl]amino)pyridine-4-carboxylic acid.
  • the substituted pyridine derivative compounds are prepared by the general synthetic routes described below in Schemes 1-3.
  • compound A and an amine compound B are mixed and treated under a variety of conditions to form compound C.
  • the mixture of compound A and an amine B can be subjected to microwave irradiation in an appropriate solvent, at temperatures ranging from 120° C. to 172° C.
  • the ester compound E can be prepared from compound C and an alcohol D using a coupling reagent, such as HATU, in the presence of a base.
  • ester compound E can be prepared from compound C and an alcohol D using a coupling reagent, such as HATU, in the presence of a base.
  • compound H and an amine compound B are mixed and treated under a variety of conditions to form compound E.
  • the mixture of compound H and an amine B can be subjected to a Buchwald reaction under microwave irradiation in an appropriate solvent, at temperatures ranging from 100° C. to 120° C.
  • the ester compound E can be hydrolyzed to give compound C, using basic conditions such as IN aqueous NaOH.
  • KGM4(i) compounds described herein may be produced or provided as a pharmaceutically acceptable salt.
  • a pharmaceutically acceptable salt of any one of the substituted pyridine derivative KGM4(i) compounds is intended to encompass any and all pharmaceutically suitable salt forms, including pharmaceutically acceptable salts such as acid and base addition salts, as are well-known in the art.
  • the substituted pyridine derivative compound exemplified by Compound I is substantially pure, in that it contains less than about 5%, or less than about 1%, or less than about 0.1%, of other organic small molecules, such as unreacted intermediates or synthesis by-products that are created, for example, in one or more of the steps of synthesis.
  • the KGM4(i) compounds described herein typically contain one or more asymmetric centers and thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that are defined, in terms of absolute stereochemistry, as (R) or (S). Likewise, all possible isomers, as well as their racemic and optically pure forms, and all tautomeric forms are also intended to be included.
  • positional isomer refers to structural isomers around a central ring, such as ortho-, meta- and para-isomers around a benzene ring.
  • a “stereoisomer” refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not interchangeable.
  • the KGM4(i) compounds provided herein encompass various stereoisomers and mixtures thereof and includes “enantiomers,” which refers to two stereoisomers whose molecular structures are non-superimposable mirror images of one another.
  • a “tautomer” refers to a molecule wherein a proton shift from one atom of a molecule to another atom of the same molecule is possible.
  • the KGM4(i) compounds presented herein may, in certain embodiments, exist as tautomers. In circumstances where tautomerization is possible, a chemical equilibrium of the tautomers may exist, but the exact ratio of the tautomers depends on factors such as physical state, temperature, solvent, and pH.
  • the KGM4(i) described herein may be produced, obtained, or formulated as a “prodrug.”
  • Prodrugs are compounds that may be inactive when administered, but are converted under physiological conditions or by hydrolysis (i.e., in vivo) to a biologically active compound; thus prodrugs are pharmaceutically acceptable precursors of a biologically active compound.
  • Prodrug compounds may offer advantages of solubility, tissue compatibility, or delayed release in a subject.
  • Prodrugs also refer to use of covalently bonded carriers that release the active compound in vivo when such prodrug is administered to the subject.
  • Prodrugs of an active compound may be prepared by modifying functional groups present in the active compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent active compound.
  • prodrugs include compounds in which a hydroxy, amino, or mercapto group is bonded to any group that, when the prodrug of the active compound is administered to a mammalian subject, cleaves to form a free hydroxy, free amino or free mercapto group, respectively.
  • Examples of prodrugs include acetate, formate, and benzoate derivatives of alcohol or amine functional groups in the active compounds.
  • a reference to KGM4(i), KGM4(i) compound, or Compound I, and the like includes within that reference a pharmaceutically acceptable salt, hydrate, solvate, N-oxide, stereoisomer, tautomer, or prodrug thereof.
  • the substituted pyridine derivative KGM4(i) compound may be administered as a pure compound.
  • the KGM4(i) compound is combined with a pharmaceutically acceptable carrier (also referred to herein as a pharmaceutically suitable (or acceptable) excipient, physiologically suitable (or acceptable) excipient, or physiologically suitable (or acceptable) carrier) selected on the basis of a chosen route of administration and standard pharmaceutical practice. See, e.g., R EMINGTON : S CIENCE & P RACTICE OF P HARMACY 21 st Ed. (Gennaro (Ed.) Mack Pub. Co., Easton, Pa., 2005).
  • a pharmaceutical composition comprising at least one substituted pyridine derivative KGM4(i) compound, or a stereoisomer, pharmaceutically acceptable salt, hydrate, solvate, tautomer, or N-oxide thereof, together with one or more pharmaceutically acceptable carriers.
  • the carrier(s) or excipient(s)
  • One embodiment provides a pharmaceutical composition comprising Compound I.
  • Example pharmaceutical agents include small molecules, chemotherapeutic agents, contrast agents, anesthetics, interfering RNAs, gene vectors, biologics, immunogens, antigens, interferons, polyclonal antibody preparations, monoclonal antibodies, insulins, or combinations of any of these.
  • a pharmaceutical composition or pharmaceutical formulation may comprise one or more active therapeutic agents, or a combination of active and diagnostic agents, etc., typically further comprising a suitable excipient(s).
  • a pharmaceutical composition as disclosed here may be formulated to be compatible with its intended route of administration.
  • routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (i.e., topical), transmucosal, and rectal administration.
  • Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose.
  • the pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
  • the parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
  • compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
  • suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, N.J., US) or phosphate buffered saline (PBS).
  • the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof.
  • the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
  • isotonic agents for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition.
  • Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
  • Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.
  • dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above.
  • methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
  • a suitable propellant e.g., a gas such as carbon dioxide, or a nebulizer.
  • Systemic administration can also be by transmucosal or transdermal means.
  • penetrants appropriate to the barrier to be permeated are used in the formulation.
  • penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives.
  • Transmucosal administration can be accomplished through the use of nasal sprays or suppositories.
  • the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.
  • the compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.
  • Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets.
  • the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules.
  • Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed.
  • Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
  • the tablets, pills, capsules, troches, and the like can contain any of the following ingredients or compounds of a similar nature: a binder such as microcrystalline cellulose, tragacanth gum, or gelatin; an excipient such as starch or lactose; a disintegrating agent such as alginic acid, P RIMOJEL ® (sodium starch glycolate, DFE pharma), or corn starch; a lubricant such as magnesium stearate, calcium stearate, glyceryl palmitostearate, or glyceryl behenate; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
  • a binder such as microcrystalline cellulose, tragacanth gum, or gelatin
  • an excipient such as starch or lactose
  • a disintegrating agent such as alginic acid, P RIMOJEL
  • an example pharmaceutical composition can be formulated in suitable oral dosage forms include, for example, tablets, pills, sachets, or capsules of hard or soft gelatin, methylcellulose or of another suitable material easily dissolved in the digestive tract.
  • suitable nontoxic solid carriers include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like. See, e.g., REMINGTON, 2005.
  • a tablet can be prepared by mixing 48% by weigh of Compound I, 45% by weight of microcrystalline cellulose, 5% by weight of low-substituted hydroxypropyl cellulose, and 2% by weight of magnesium stearate. Tablets can be prepared by direct compression. The total weight of this example of compressed tablets is maintained at 250-500 mg. Oral doses may typically range from about 1.0 mg to about 1000 mg, one to four times, or more, per day.
  • the KDM4(i) compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as sustained/controlled release formulations, including implants and microencapsulated delivery systems.
  • sustained/controlled release formulations including implants and microencapsulated delivery systems.
  • Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art.
  • the active ingredients can be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles, and nanocapsules) or in macroemulsions.
  • colloidal drug delivery systems for example, liposomes, albumin microspheres, microemulsions, nano-particles, and nanocapsules
  • sustained-release preparations can be prepared, and suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, or microcapsules.
  • sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No.
  • copolymers of L-glutamic acid and y ethyl-L-glutamate non-degradable ethylene-vinyl acetate
  • degradable lactic acid-glycolic acid copolymers such as the L UPRON D EPOT ® (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate)
  • poly-D-( ⁇ )-3-hydroxybutyric acid While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods.
  • Liposomal suspensions can also be used as pharmaceutically acceptable carriers. These preparations can be prepared according to methods known to those skilled in the art.
  • Oral or parenteral compositions may be formulated in dosage unit form for ease of administration and uniformity of dosage.
  • Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • the specification for the dosage unit forms disclosed here are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.
  • compositions or dosage units can be included in a container, pack, or dispenser together with instructions for administration.
  • the formulation can also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other.
  • the composition can comprise an agent that enhances its function, such as, for example, an immunostimulatory agent, chemotherapeutic agent, cytokine, antibody, or growth-inhibitory agent.
  • an agent that enhances its function such as, for example, an immunostimulatory agent, chemotherapeutic agent, cytokine, antibody, or growth-inhibitory agent.
  • Such molecules are suitably present in combination in amounts that are effective for the purpose intended.
  • a “pharmaceutical formulation,” “formulation,” or “pharmaceutical composition” refers to a drug product that includes at least one active agent and may further include at least one pharmaceutically acceptable excipient, carrier, buffer, stabilizer, or other material well-known to those skilled in the art.
  • a typical injectable pharmaceutical formulation includes a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity, and stability.
  • Pharmaceutical compositions can have diagnostic, therapeutic, or research utility in various species, such as for example in human patients or subjects.
  • a pharmaceutical composition comprises a bromodomain inhibitor and a chemotherapeutic agent such as temozolomide, protein-bound paclitaxel, or romidepsin.
  • a bromodomain inhibitor may be 4-[2-(cyclopropylmethylamino)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one.
  • the agents and compositions described herein can be formulated by any conventional manner using one or more pharmaceutically acceptable carriers or excipients as described in accepted literature. See, e.g., REMINGTON: SCIENCE & PRACTICE OF PHARMACY, 22nd Ed. (Lloyd (Ed.), Pharmaceutical Press, London, U K, 2012).
  • Such formulations contain a therapeutically effective amount of an active agent(s) described herein, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the subject.
  • a pharmaceutical formulation can include a therapeutically effective amount of at least one active agent.
  • Such effective amounts can be readily determined by one of ordinary skill in the art based, in part, on the effect of the administered dosage form, or the combinatorial effect of an agent and one or more additional active agents, if more than one agent is used.
  • a therapeutically effective amount of an active agent can also vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the agent (and one or more additional active agents) to elicit a desired response in the individual, e.g., amelioration of at least one condition parameter.
  • a therapeutically effective amount of a dosage form can inhibit (lessen the severity of or eliminate the occurrence of), prevent a particular disorder, or lessen any one of the symptoms of a particular disorder known in the art or described herein.
  • a therapeutically effective amount may also be one in which any toxic or detrimental effects of the active agent or dosage form are outweighed by the therapeutically beneficial effects.
  • compositions are administered in a manner appropriate to the condition treated (see below).
  • An appropriate dose and suitable duration and frequency of dose administration can be determined based on the condition of the subject, the type and severity of the subject's disease, the particular form of the active compound, and the method of administration.
  • an appropriate dose and treatment regimen provides active composition(s) in an amount sufficient to provide therapeutic or prophylactic benefit (e.g., an improved clinical outcome, such as more frequent complete or partial remissions, or longer disease-free or overall survival, or a lessening of symptom severity, see below).
  • Optimal doses are generally determined using experimental models or clinical trials, then adjusted for the body mass, weight, or blood volume of the subject.
  • the dose of the pharmaceutical composition comprising at least one substituted pyridine derivative KDM4(i) compound may differ depending upon the condition of the subject (e.g., human patient), such as stage of the disease, general health status, age, and other factors.
  • the KDM4(i) compounds as disclosed here may be administered in combination therapy, i.e., combined with other agents, e.g., therapeutic agents, that are useful for treating pathological conditions or disorders, such as various forms of cancer, autoimmune disorders and inflammatory diseases.
  • agents e.g., therapeutic agents
  • the term “in combination” in this context means that the agents are given substantially contemporaneously, either simultaneously or sequentially. If given sequentially, at the onset of administration of the second compound, the first of the two compounds is preferably still detectable at effective concentrations at the site of treatment.
  • the combination therapy can include one or more antibodies disclosed here coformulated with, or coadministered with, one or more additional therapeutic agents, e.g., one or more cytokine and growth factor inhibitors, immunosuppressants, anti-inflammatory agents, metabolic inhibitors, enzyme inhibitors, or cytotoxic or cytostatic agents.
  • additional therapeutic agents e.g., one or more cytokine and growth factor inhibitors, immunosuppressants, anti-inflammatory agents, metabolic inhibitors, enzyme inhibitors, or cytotoxic or cytostatic agents.
  • Such combination therapies may advantageously utilize lower dosages of the administered therapeutic agents, thus avoiding possible toxicities or complications associated with the various monotherapies.
  • a therapeutic KDM4(i) compound disclosed here may be used in combination with an antibody and further include those agents that interfere at different stages in an inflammatory response.
  • KDM4(i) compounds described herein may be coformulated with, or coadministered with, one or more additional agents such as other chemotherapeutic agents, or biologics such as vaccines, immunotoxins, cytokine or growth factor antagonists (e.g., soluble receptors, peptide inhibitors, small molecules, ligand fusions); antibodies or antigen binding portions thereof (e.g., antibodies that bind to tumor markers, cytokines or growth factors or their receptors); and anti-inflammatory cytokines or agonists thereof.
  • additional agents such as other chemotherapeutic agents, or biologics such as vaccines, immunotoxins, cytokine or growth factor antagonists (e.g., soluble receptors, peptide inhibitors, small molecules, ligand fusions); antibodies or antigen binding portions thereof (e.g., antibodies that bind to tumor markers, cytokines or growth factors or their receptors); and anti-inflammatory cytokines or agonists thereof.
  • a KDM4(i) compound can be co-formulated or coadministered with at least one additional chemotherapeutic agent.
  • the chemotherapeutic agent may be a bromodomain inhibitor (see, e.g., WO 2015058160; Patent Pub. No. US 20150111885; U.S. Pat. No. 9,034,900), an alkylating agent, or a mitotic inhibitor.
  • an active agent i.e., KDM4(i) compound
  • a KDM4(i) compound can be administered to a subject as a monotherapy, or as a combination therapy with another active agent in a combination dosage form, or as an additional treatment, e.g., another treatment for the same, an associated, or an additional disorder.
  • a KDM4(i) compound can be combined with a chemotherapeutic agent, such as a bromodomain inhibitor, romidepsin, temozolomide, protein-bound paclitaxel, and the like, in the same formulation, or in a different formulation administered simultaneously or sequentially.
  • combination therapy can include administering to the subject (e.g., a human patient) one or more agents (e.g., antibiotics, anti-coagulants, anti-hypertensives, or anti-inflammatory drugs) that provide a therapeutic benefit to subject.
  • agents e.g., antibiotics, anti-coagulants, anti-hypertensives, or anti-inflammatory drugs
  • combination therapy can include administering to the subject a KDM4(i) compound and one or more additional agents that provide therapeutic benefit to a subject who has cancer, such as triple-negative or refractory breast cancer.
  • combination therapy can include administering to the subject a KDM4(i) compound, protein-bound paclitaxel, or a combination comprising a KDM4(i) compound and paclitaxel, and one or more additional agents that provide therapeutic benefit to a subject who has cancer.
  • an active agent is administered first in time and an additional active agent(s) is administered second in time.
  • one or more additional active agents are administered at the same time, but using different drug delivery devices or delivery modes, for example, providing for combination therapy comprising administration of a KDM4(i) compound and temozolomide, or comprising a KDM4(i) compound and paclitaxel, or comprising a KDM4(i) compound and romidepsin.
  • the KDM4(i) compound is Compound I.
  • Cancers that may be treated with therapy including administration of KDM4(i) compounds include carcinoma, sarcoma, germ cell tumor, lymphoma or leukemia, blastoma, or other cancers.
  • Carcinomas include epithelial and glandular neoplasms, transitional cell carcinoma, adenoid cystic carcinoma, insulinoma, hepatocellular carcinoma, cholangiocarcinoma, carcinoid tumor of appendix, linitis plastica, larynx carcinoma, hypopharynx carcinoma, mouth cancer, hypopharyngeal cancer, salivary gland carcinoma, tongue carcinoma, gastric carcinoma, prolactinoma, oncocytoma, hepatocellular carcinoma, kidney parenchyma carcinoma, papillary renal carcinoma, gall bladder carcinoma, bronchial carcinoma, Grawitz tumor, carcinoma of unknown primary site, multiple endocrine adenomas, endometrioid adenoma, adnexal and skin appendage neoplasms,
  • Sarcomas include Askin's tumor, botryodies, Ewing's sarcoma, Kaposi's sarcoma, malignant hemangio endothelioma, malignant schwannoma, osteosarcoma, soft tissue sarcomas (including alveolar soft part sarcoma, angiosarcoma, cystosarcoma phyllodes, dermatofibrosarcoma, desmoid tumor, desmoplastic small round cell tumor, epithelioid sarcoma, extraskeletal chondrosarcoma, extraskeletal osteosarcoma, hemangiopericytoma, hemangiosarcoma, lymphangiosarcoma, lympho-sarcoma, malignant fibrous histiocytoma, neurofibrosarcoma, and synovial sarcoma).
  • Lymphoma and leukemia include acute lymphoblastic leukemia, acute myeloid leukemia, hairy cell leukemia, multiple myeloma, chronic myelogenous leukemia; chronic myeloproliferative disorders; chronic lymphocytic leukemia/small lymphocytic lymphoma, B-cell prolymphocytic leukemia, lympho-plasmacytic lymphoma (such as Waldenstrom macroglobulinemia), splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, monoclonal immunoglobulin deposition diseases, heavy chain diseases, extranodal marginal zone B-cell lymphoma, also called malt lymphoma, nodal marginal zone B-cell lymphoma, Burkitt's lymphoma, non-Hodgkin lymphoma (including diffuse large B-cell lymphoma, follicular lymphoma, Mycosis fungoides and the Sezary syndrome, mantle cell
  • Germ cell tumors include without limitation germinoma, dysgerminoma, nongerminomatous germ cell tumor, endodermal sinus turmor, extracranial germ cell tumor; extragonadal germ cell tumor, teratoma, polyembryoma, and gonadoblastoma.
  • Blastomas include ependymoblastoma, esthesioneuroblastoma, and nephroblastoma.
  • lung cancers such as non-small cell lung cancer and small cell lung cancer (including small cell carcinoma (oat cell cancer), mixed small cell/large cell carcinoma, and combined small cell carcinoma), liver cancer, gastric cancer, glioblastoma, head and neck squamous cell carcinoma, myeloma, adrenocortical carcinoma; thyroid cancer (medullary and papillary thyroid carcinoma), renal carcinoma, cervix carcinoma, uterine corpus carcinoma, endometrium carcinoma, chorion carcinoma, testis carcinoma, urinary carcinoma, melanoma, basalioma, teratoma, choroidea melanoma, craniopharyngeoma, osteosarcoma, myosarcoma, and plasmocytoma, anal cancer; appendix cancer; atypical teratoid/rhabdoid tumor; bladder cancer; brain tumor (including brain stem glioma, central nervous tissue), and atypical teratoid/rhabdoid tumor; bladder
  • cancers associated with hard tumors that may be treated with substituted pyridine derivative KDM4(i) compounds include breast cancer, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon cancer, colorectal cancer, kidney cancer, pancreatic cancers (such as glucagonoma, gastrinoma, pancreatic neuroendocrine tumor (VIPoma)), bone cancer, ovarian cancer, prostate cancer, esophageal cancer, stomach cancer, oral cancer, nasal cancer, throat cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma,
  • Chemotherapeutic agents are often characterized by functionality, chemical structure, and relationship to another drug.
  • Chemotherapeutic agents include, for example: alkylating agents (e.g., azacitidine, nitrogen mustards: mechlorethamine, chlorambucil, cyclophosphamide (C YTOXAN ®), ifosfamide, bendamustine (L EVACT ®) and melphalan; nitrosoureas: streptozocin, carmustine (BCNU), lomustine, and bischloroethylnitrosurea; alkyl sulfonates: busulfan, triazines: dacarbazine (DTIC) and temozolomide (T EMODAR ®); ethylenimines: thiotepa and altretamine (hexamethylmelamine); platinum drugs (such as cisplatin, carboplatin, satraplatin (JM-216), CI-973,
  • Additional anticancer therapies that may be combined with BET inhibitor therapy include surgery, radiotherapy (e.g., gamma-radiation, neutron bean radiotherapy, electron beam radiotherapy, proton therapy, brachytherapy, and systemic radioactive isotopes), endocrine therapy, biological response modifiers (e.g., interferons, interleukins, and tumor necrosis factor), hyperthermia and cryotherapy, and agents to attenuate any adverse effects (e.g., anti-emetics).
  • radiotherapy e.g., gamma-radiation, neutron bean radiotherapy, electron beam radiotherapy, proton therapy, brachytherapy, and systemic radioactive isotopes
  • endocrine therapy e.g., gamma-radiation, neutron bean radiotherapy, electron beam radiotherapy, proton therapy, brachytherapy, and systemic radioactive isotopes
  • biological response modifiers e.g., interferons, interleukins, and tumor necrosis
  • chemotherapeutic agent herein applies to the chemotherapeutic agent or its derivatives and accordingly the invention contemplates and includes either of these embodiments (agent; agent or derivative(s)).
  • “Derivatives” or “analogs” of a chemotherapeutic agent or other chemical moiety include, but are not limited to, compounds that are structurally similar to the chemotherapeutic agent or moiety or are in the same general chemical class as the chemotherapeutic agent or moiety.
  • the derivative or analog of the chemotherapeutic agent or moiety retains similar chemical or physical property (including, for example, functionality) of the chemotherapeutic agent or moiety.
  • Administration of a pharmaceutical composition comprising a KDM4(i) compound may replace or augment a previously or currently administered therapy.
  • administration of an additional active agent(s) can cease or be diminished, e.g., be administered at lower concentrations or with longer intervals between administrations.
  • administration of a previous therapy can be maintained.
  • a previous therapy is maintained until the level of an active agent reaches a level sufficient to provide a therapeutic effect. Accordingly, two therapies can be administered in combination, sequentially, or simultaneously.
  • administration of a KDM4(i) in combination with an additional active agent may provide a synergistic therapeutic result. Combined therapy provided may be administered at once or multiple times at intervals of time.
  • dosage and duration of treatment may vary with the age, weight, and condition of the patient being treated, and may be determined empirically using known testing protocols or by extrapolation from in vivo or in vitro test or diagnostic data. It is further understood that for any particular individual, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the formulations.
  • subject or “patient” as used herein refer to any subject, particularly a mammalian subject, for whom diagnosis, prognosis, or therapy of a cancer, such as a breast cancer, particularly triple-negative breast cancer is relevant.
  • subject or “patient” may include any human or nonhuman animal as context indicates.
  • treat As used herein, “treat,” “treatment,” “treating,” “palliating,” “ameliorating,” or “treatment of” are used interchangeably and refer, in general, therapeutic benefit or prophylactic benefit, e.g., reducing the potential for disease, reducing the occurrence of disease, or reducing the severity of disease.
  • treating can refer to the ability of a therapy when administered to a subject, to prevent further tumor growth or malignancy, or to cure or to alleviate at least partially a disease symptom, sign, or cause.
  • These terms refer to an approach for obtaining beneficial or desired results including but not limited to therapeutic benefit or a prophylactic benefit.
  • “Therapeutic benefit” generally means eradication or amelioration of the underlying disorder being treated.
  • a therapeutic benefit may also be achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the patient, notwithstanding that the patient is still afflicted with the underlying disorder.
  • a therapeutic benefit is not necessarily a cure for a particular cancer, but rather encompasses a result that most typically includes alleviation; increased survival; elimination of a tumor; reduction of a symptom associated with a cancer; prevention or alleviation of a secondary disease, disorder, or condition resulting from the occurrence of a cancer; or prevention of metastasis.
  • compositions may be administered to a patient at risk of developing a particular disease, or to a patient reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease has not been made.
  • therapeutic agent refers to any therapeutically active substance that is administered to a subject to produce a desired, usually beneficial, effect.
  • therapeutic agent includes, e.g., classical low molecular weight therapeutic agents commonly referred to as small molecule drugs; and biologics including, but not limited to, antibodies or functionally active portions thereof, peptides, lipids, protein drugs, protein conjugate drugs, fusion proteins, enzymes, nucleic acids, ribozymes, genetic material, viruses, bacteria, eukaryotic cells, and vaccines.
  • a therapeutic agent can also be a pro-drug.
  • a therapeutic agent can also be a radioactive isotope.
  • a therapeutic agent can be an agent activated by a form of energy such as light or ultrasonic energy, or activated by other circulating molecules that can be administered systemically or locally.
  • the therapeutic agent can be pharmaceutically formulated.
  • Patient breast cancer tumor material was obtained from the pathology department of the University Medical Centre Freiburg with patient consent (Ethics vote 307/13). All primary tumors were from subjects who had received chemotherapy before tissue collection and were classified as triple-negative. All surgeries were conducted by the Department of Obstetrics and Gynecology at the University Medical Centre Freiburg. Tumor tissue specimens for engraftment and paraffin embedding were obtained simultaneously through pathologists from the tumor bank of the Comprehensive Cancer Centre Freiburg. Written informed consent was obtained from all patients before inclusion in studies described herein.
  • BCSC Primary breast cancer stem cells
  • the digest medium was diluted with 10 ml DPBS and filtered through a cell strainer (40 ⁇ m, Becton Dickenson, Carlsbad, Calif., US), and remaining tissue clumps smashed with a piston from a 2 mL syringe. Following centrifugation at 200 g for 5 min, the supernatant was discarded and the cell pellet washed once with MEBM medium (G IBCO ). If red blood cells were visible in the pellet, 1 mL ACK Lysis buffer (G IBCO ) was added to the cell pellet. After 1 min incubation at room temp, up to 6 mL MEBM was added and the preparation centrifuged at 200 g for 5 min.
  • MEBM medium G IBCO
  • the pellet was resuspended in 1 mL MEBM and filtered through a 40 m strainer. Following centrifugation at 200 g for 5 min, the supernatant was discarded and remaining cell pellet taken up in mammary stem-cell (MSC, see below) medium. Cells were counted in a Neubauer chamber (hemocytometer), then plated in a 24-well low attachment plate (C ORNING ®, Corning, N.Y., US) at 2 ⁇ 10 4 cells per well in an ice-cold 1:1 mix of MSC medium and M ATRIGEL ® matrix (C ORNING , #354230). After solidification of M ATRIGEL at 37° C.
  • C ORNING ® Corning, N.Y., US
  • each well was topped with 500 ⁇ L MSC medium.
  • the cells were cultured at 37° C. under low-oxygen conditions (3% O 2 , 5% CO 2 , 92% N 2 ). When cells proliferated stably in 3D, they were cultured in 2D culture for cell expansion.
  • MSC mammary stem-cell
  • G IBCO mammary epithelial basal medium
  • B27® serum-free cell culture supplement G IBCO , #17504-044
  • amphotericin B SIGMA-ALDRICH, # A2942
  • penicillin-streptomycin G IBCO , #15140122.
  • This medium was further supplemented with epidermal growth factor (f.c. 20 ng/mL, # AF-100-15, PeproTech, Rocky Hill, N.J., US), heparin (f.c.
  • fibroblast growth factor f.c. 20 ng/ml, PeproTech # AF-100-18B
  • gentamicin f.c. g/ml, G IBCO #15750-045
  • Rho kinase inhibitor f.c. 500 nM, CALBIOCHEM® #555550, Merck KGaA, Darmstadt, DE
  • High titer adenoviral preparations were obtained from Vector BioLabs (Malvern, Pa., US). Adenoviral particles were added (in MSC medium) to a multiplicity of infection (MOI) of 300 for BCSC1 cells, and a MOI of 150 for BCSC2 cells.
  • MOI multiplicity of infection
  • cells were detached by A CCUTASE solution dissociation and counted.
  • the wells of a black 384-well plate (Greiner Bio-One, Monroe, N.C., US) were coated with 10 ⁇ L of MSC medium containing 2% M ATRIGEL (354230, Corning). After incubation at 37° C. for 30 min to solidify the M ATRIGEL , 1 ⁇ 10 3 single cells were seeded per 384-well in 40 ⁇ L medium. After 24 hr under normal culture conditions, the KDM4(i) inhibitor (Compound I, Celgene Quanticel Research, Inc.) was added in 50 ⁇ L to each well to the final indicated concentrations.
  • the KDM4(i) inhibitor Compound I, Celgene Quanticel Research, Inc.
  • DAPI Sigma-Aldrich
  • BCSCs tagged with a stable NLS-mCherry fluorescent signal were used for this assay.
  • Cells were detached by A CCUTASE dissociation and counted.
  • Each well of a black 384-well plate (Greiner) was coated with 10 ⁇ L of MSC medium containing 2% M ATRIGEL . After incubation at 37° C. for 30 min to solidify the M ATRIGEL , 1 ⁇ 10 3 single cells/well were seeded in 40 ⁇ L medium. After 24 hr normal culture, the KDM4(i) was added in 50 ⁇ L to each well to the final indicated concentrations.
  • RNA was isolated from patient material, xenografts and cells using the GeneMATRIX Universal RNA Purification Kit (Roboklon GmbH, Berlin, DE) according to manufacturer instruction. Isolated RNAs were processed with the AMBIONTM WT Expression kit (Thermo-Fisher) as described by the manufacturer and hybridized to I LLUMINA ® HT-12 v.4 Expression Bead Chips following standard protocol (Illumina, Inc., San Diego, Calif. US). Expression data were processed and quantile normalized using the R/Bioconductor Beadarray package (PMID: 17586828) v2.22.
  • Chromatin immunoprecipitation (ChIP) KDM4(i) assays were performed essentially as described. Metzger et al., LSD 1 demethylates repressive histone marks to promote androgen receptor - dependent transcription, 437 Nature 436 (2005). BCSC1 cells were cultured for 18 hr in the absence or presence of 5 ⁇ 10 ⁇ 10 M KDM4(i). Three days before harvesting, cells were infected with adenovirus expressing either shRNA against KDM4A or scrambled control shRNA (Ad-GFP-U6-hKDM4AshRNA and Ad-U6-RNAi-GFP, Vector Biolabs) according to manufacturer instructions.
  • Immunoprecipitation was performed with specific antibodies, anti-KDM4A (Schuele Lab. #5766, lot 5766), anti-H3K9me3 (# C15410056, lot A1675-001P, Diagenode), on GammaBindTM G-SepharoseTM (GE-Healthcare). Libraries were prepared from immunoprecipitated DNA according to standard methods. ChIP-seq libraries were sequenced using a HiSeq 2000 (Illumina) and mapped to the hg19 reference genome using Bowtie2 software (e.g., Johns Hopkins Univ., Baltimore, Md., US).
  • the uniquely mapped reads were used to generate the genome-wide intensity profiles, which were visualized using the Integrative Genomics Viewer (IGV) genome browser (e.g., Broad Inst., Cambridge, Mass. US). Thorvaldsdottir et al., Integrative Genomics Viewer ( IGV ): high - performance genomics data visualization and exploration, 14 Brief Bioinform. 178 (2013).
  • HOMER software e.g., Univ. Calif. San Diego
  • Heinz et al. Simple combinations of lineage - determining transcription factors prime cis - regulatory elements required for macrophage and B cell identities, 38 Mol. Cell 576 (2010).
  • genomic features promoter, exon, intron, 3′UTR, and intergenic regions
  • Reference Sequence RefSeq
  • BCSC lines 1 and 2 were treated with 50 nM KDM4(i) for different time points (24 hr, 48 hr, 72 hr, and 96 hr). Following drug exposure, 4 ⁇ 10 5 cells were collected and stained with 50 ⁇ L propidium iodide (PI) using the PI/RNase solution (Cell Signaling Technol. #4087), according to manufacturer instruction. Cells were analyzed using BD LSR Fortessa and BD FACS Diva Software (Becton Dickinson). The percentage of cells in subG1 G0/G1, S and G2/M phases were determined from 1 ⁇ 10 5 ungated cells using FlowJo software v6.
  • PI propidium iodide
  • Apoptosis was detected using a FITC Annexin V Apoptosis Detection Kit I (BD Bioscience) according to manufacturer instruction.
  • cells were collected with 0.05% trypsin-EDTA solution, washed, and diluted to 1 ⁇ 10 6 cells per ml in 1 ⁇ Binding Buffer. Staining was performed for 15 min at room temp in the dark by adding 5 ⁇ L FITC-coupled antibody solution and 5 ⁇ L PI to the cells in 100 ⁇ L binding buffer. Afterwards, 400 ⁇ L binding buffer was added, and cells were analyzed using a BD LSR Fortessa and BD FACS Diva Software (Becton Dickinson). A total of 1 ⁇ 10 5 cells were counted. Analysis was performed with FlowJo software v6.
  • Example 3 In Vivo Tumorigenicity Assay in NOD/SCID Mice Bearing Orthotopic BC Xenografts
  • NOD/SCID females (4-5 weeks old) were anesthetized using an isoflurane inhalator. A small sagittal incision (no longer than 1.0 cm) on the shaved and sterilized abdomen allowed access to the mammary glands #4 on both sides.
  • Tumor cells were mixed with 1 ⁇ 10 6 irradiated fibroblasts (newborn human foreskin fibroblasts (NuFF), p11, Global Stem, GSC-3002) each, and suspended in a 1:1 mixture of Matrigel:MSC medium. The volume of each transplant was 40 ⁇ L per gland, containing defined numbers of BCSCs and 1 ⁇ 10 6 fibroblasts.
  • the transplant was injected into the mammary fat pad of the #4 gland on both sides of the animal using a 1 mL syringe with a fine needle. Each transplant was localized distal to the lymph node in the gland. Surgical incisions were sealed by suturing with a 5/0 thread (Ethicon, Z995). Animals were monitored twice weekly for animal weight and tumor growth, which was determined by caliper. Tumor volumes were calculated using the formula: 4/3 ⁇ r 3 .
  • Tumor size was monitored using ultrasound measurements gathered using a small animal high resolution ultrasound system (Vevo3100) and transducer (MX550D) with 40 MHz (VisualSonics, Toronto, Canada).
  • Vevo3100 small animal high resolution ultrasound system
  • MX550D transducer
  • the transducer was moved along the tumor automatically with a step size of 0.076 mm. Representative pictures showed qualitative tumor differences as visualized with Vevo LAB v.1.7.1 at beginning and end of treatment.
  • SIGMA polyethylene glycol
  • DPBS 50% DPBS
  • tissue specimens were immediately formalin fixed (10%). After formalin fixation and paraffin embedding 2 m thick sections were cut and mounted onto cover slips. All cover slips were stored for two days at 58° C. in a drying chamber, subsequently deparaffinized using xylene and hydrated with ethanol.
  • ENVISION® Flex Peroxidase-Blocking Reagent DAKO, SM801
  • ENVISION® Flex+Rabbit LINKER
  • ENVISION® Flex+Mouse LINKER
  • ENVISION® Flex/HRP DAKO, SM802
  • Counterstaining was performed with hemalum before adding a coverslip.
  • patient-derived physiological mammary gland was used for ER, PR, Ki-67 (nuclear staining), cytokeratin 8/18, and E-Cadherin (membranous cytoplasmic staining).
  • the mammary gland-surrounding myoepithelial layer was used as internal control for Vimentin.
  • tissue specimens from HER2 positive breast cancer patients (Score 3 according to Ref 20 ) were carried for every HER2 staining session as external positive control.
  • Triple-negative breast cancer was defined as ER, PR and HER2 negative (score ⁇ 2) breast cancer.
  • RNA samples were sequenced by the standard Illumina protocol to create raw sequence files (.fastq files) at the sequencing core facility of the DKFZ. These reads were aligned to the hg19 build of the human genome using TopHat version 2. The aligned reads were counted with the Homer software (analyze RNA) and DEG's were identified using EdgeR and DESeq version 1.8.3. Data are deposited under GSE.
  • Compound I 3-( ⁇ [6-[methyl(phenyl)amino]-1,2,3,4-tetrahydronaphthalen-1-yl]methyl ⁇ amino) pyridine-4-carboxylic acid (Compound I) can be carried out, for example, based on the method described in U.S. Pat. No. 9,447,046. Briefly, Compound I can be prepared according to the following preparations:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
US16/498,714 2017-03-30 2018-03-27 Kdm4 inhibitors Abandoned US20200039938A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/498,714 US20200039938A1 (en) 2017-03-30 2018-03-27 Kdm4 inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762478785P 2017-03-30 2017-03-30
US201762513875P 2017-06-01 2017-06-01
PCT/US2018/024624 WO2018183370A2 (en) 2017-03-30 2018-03-27 Kdm4 inhibitors
US16/498,714 US20200039938A1 (en) 2017-03-30 2018-03-27 Kdm4 inhibitors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/024624 A-371-Of-International WO2018183370A2 (en) 2017-03-30 2018-03-27 Kdm4 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/749,233 Continuation US20240076271A1 (en) 2017-03-30 2022-05-20 Kdm4 inhibitors

Publications (1)

Publication Number Publication Date
US20200039938A1 true US20200039938A1 (en) 2020-02-06

Family

ID=63678220

Family Applications (3)

Application Number Title Priority Date Filing Date
US16/498,714 Abandoned US20200039938A1 (en) 2017-03-30 2018-03-27 Kdm4 inhibitors
US15/936,811 Abandoned US20180290977A1 (en) 2017-03-30 2018-03-27 Kdm4 inhibitors
US17/749,233 Pending US20240076271A1 (en) 2017-03-30 2022-05-20 Kdm4 inhibitors

Family Applications After (2)

Application Number Title Priority Date Filing Date
US15/936,811 Abandoned US20180290977A1 (en) 2017-03-30 2018-03-27 Kdm4 inhibitors
US17/749,233 Pending US20240076271A1 (en) 2017-03-30 2022-05-20 Kdm4 inhibitors

Country Status (6)

Country Link
US (3) US20200039938A1 (enExample)
EP (1) EP3600301B1 (enExample)
JP (1) JP7442439B2 (enExample)
ES (1) ES2991090T3 (enExample)
TW (1) TWI814723B (enExample)
WO (1) WO2018183370A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023122221A1 (en) * 2021-12-23 2023-06-29 Tachyon Therapeutics, Inc. Pharmaceutical formulations comprising 3-({[(4r)-7-{methyl[4-(propan-2-yl)phenyl]amino}-3,4-dihydro-2h-l-benzopyran-4-yl]methyl}amino)pyridine-4-carboxylic acid
WO2024064734A1 (en) * 2022-09-21 2024-03-28 Celgene Corporation Crystalline forms of 3-({[(4r)-7-{methyl[4-(propan-2- yl)phenyl]amino}-3,4-dihydro-2h-l-benzopyran-4- yl]methyl}amino)pyridine-4-carboxylic acid l-lysine salt, a histone demethylase inhibitor

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015279719B2 (en) * 2014-06-25 2019-03-21 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
CN113876953B (zh) * 2020-07-02 2022-12-09 中国科学院上海营养与健康研究所 新型细胞衰老干预靶点及其在化疗抗癌中的靶向应用
WO2022217100A1 (en) * 2021-04-09 2022-10-13 Tachyon Therapeutics, Inc. Treatment of cancer with kdm4 inhibitors
EP4387961A1 (en) * 2021-08-18 2024-06-26 Celgene Corporation Process for preparing histone demethylase inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
EP2712316A1 (en) * 2011-02-08 2014-04-02 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders
HK1210611A1 (en) * 2012-12-21 2016-04-29 Quanticel Pharmaceuticals Inc Histone demethylase inhibitors
PE20161065A1 (es) 2013-10-18 2016-11-19 Celgene Quanticel Res Inc Inhibidores de bromodominio
US9890434B2 (en) * 2014-03-19 2018-02-13 National Tsing Hua University Method for identifying compound for inhibiting an activity of a histone lysine demethylase
AR099890A1 (es) * 2014-03-31 2016-08-24 Epitherapeutics Aps Inhibidores de histona demetilasas
DK3137169T3 (da) 2014-05-01 2022-02-14 Celgene Quanticel Res Inc Hæmmere af lysin-specifik demethylase-1
AU2015279719B2 (en) * 2014-06-25 2019-03-21 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
CN108698997A (zh) * 2015-12-28 2018-10-23 赛尔基因昆蒂赛尔研究公司 组蛋白脱甲基酶抑制剂

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023122221A1 (en) * 2021-12-23 2023-06-29 Tachyon Therapeutics, Inc. Pharmaceutical formulations comprising 3-({[(4r)-7-{methyl[4-(propan-2-yl)phenyl]amino}-3,4-dihydro-2h-l-benzopyran-4-yl]methyl}amino)pyridine-4-carboxylic acid
WO2024064734A1 (en) * 2022-09-21 2024-03-28 Celgene Corporation Crystalline forms of 3-({[(4r)-7-{methyl[4-(propan-2- yl)phenyl]amino}-3,4-dihydro-2h-l-benzopyran-4- yl]methyl}amino)pyridine-4-carboxylic acid l-lysine salt, a histone demethylase inhibitor

Also Published As

Publication number Publication date
EP3600301B1 (en) 2024-07-03
TW201840537A (zh) 2018-11-16
EP3600301A2 (en) 2020-02-05
US20240076271A1 (en) 2024-03-07
WO2018183370A3 (en) 2018-12-20
JP7442439B2 (ja) 2024-03-04
EP3600301A4 (en) 2020-08-12
TWI814723B (zh) 2023-09-11
JP2020515645A (ja) 2020-05-28
ES2991090T3 (es) 2024-12-02
WO2018183370A2 (en) 2018-10-04
US20180290977A1 (en) 2018-10-11

Similar Documents

Publication Publication Date Title
US20240076271A1 (en) Kdm4 inhibitors
JP6046702B2 (ja) 脳腫瘍の処置用のｃｓｆ−１ｒ阻害剤
JP2022017495A (ja) 癌を治療するための併用療法
US20240207202A1 (en) Combination therapies targeting mitochondrial biogenesis for cancer therapy
US20180085348A1 (en) Methods for treating cancer with rorgamma inhibitors
US10512642B2 (en) Therapeutic targeting of myeloproliferative neoplasms by DUSP1 inhibition
US20100150844A1 (en) Use of 8-quinolinol and its analogs to target cancer stem cells
AU2019204363A1 (en) Icariin derivatives
AU2016246521A1 (en) Treatment of lung cancer with inhibitors of glutaminase
KR20220123064A (ko) Cdk12/13 억제제에 의한 암 치료
CN116437919B (zh) 用组织蛋白酶c抑制剂治疗转移的方法
Joshi et al. Design and synthesis of topoisomerases-histone deacetylase dual targeted quinoline-bridged hydroxamates as anticancer agents
WO2021011800A1 (en) Method of treating neoplastic diseases with a cdc42-specific inhibitor
US11427543B2 (en) Compounds for targeting cancer stem cells
EP2397149A1 (en) Pharmaceutical preparation comprising actinomycin D for the treatment of B-CLL in patients having del(17p)
US10213449B2 (en) Compositions and methods for treating medulloblastoma
CN115607674B (zh) Rna解旋酶dhx33抑制剂在制备用于治疗胰腺癌的药物中的应用
Xie et al. Diallyl Trisulfide Suppresses Tumor‐Associated Macrophage M2‐Like Polarization and Recruitment and Improves the Tumor Microenvironment Through Blocking CCL5/STAT3 Signaling Pathway Against Lung Cancer
WO2025199440A1 (en) Methods of treating liposarcoma using a pyrazole compound
WO2025024377A1 (en) Inhibitors of rna binding protein igf2bp3
CN107849033A (zh) 用于治疗Rac‑GTP酶介导的病症的化合物
JP2023547108A (ja) γサブユニットを標的とするミトコンドリアＡＴＰ阻害剤は転移を予防する
Yang MDM2 Degradation as a Novel and Efficacious Cancer Therapy
TW201208668A (en) Compounds for the treatment of cancer and its application

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: AWAITING TC RESP., ISSUE FEE NOT PAID

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE

AS Assignment

Owner name: CELGENE QUANTICEL RESEARCH, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SCHUELE, ROLAND;METZGER, ERIC;SIGNING DATES FROM 20231025 TO 20231102;REEL/FRAME:065496/0055

Owner name: ALBERT-LUDWIGS-UNIVERSITY FREIBURG, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SCHUELE, ROLAND;METZGER, ERIC;SIGNING DATES FROM 20231025 TO 20231102;REEL/FRAME:065496/0055